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ABSTRACT	
	
	
Pathologic	and	Prognostic	Implications	of	Incidental	vs.	Non-Incidental	Gallbladder	Cancer:	
A	10-Institution	Study	from	the	U.S.	Extrahepatic	Biliary	Malignancy	Consortium	
	
	
By	
	
	
Nina	Le	
	
	
April	21,	2017	
	
	
BACKGROUND		
	
Most	gallbladder	cancers	(GBC)	are	discovered	incidentally	after	routine	cholecystectomy.	The	
relationship	between	the	method	of	diagnosis	and	disease	stage,	treatment,	and	prognosis	are	not	
known.	
	
METHODS	
	
Patients	with	GBC	who	underwent	resection	at	10	institutions	from	2000-2015	were	included.	Patients	
diagnosed	incidentally	(IGBC)	and	non-incidentally	(non-IGBC)	were	compared.	Primary	outcome	was	
overall	survival	(OS).	
	
RESULTS	
	
Of	445	patients	with	GBC,	266	(60%)	were	IGBC	and	179	(40%)	were	non-IGBC.	Compared	to	IGBC,	non-
IGBC	patients	were	more	likely	to	have	R2	(macroscopic	residual	disease)	resections	(43	vs.	19%;	
p<0.001),	advanced	tumor	(T)	stage	(T3/T4:	70	vs.	40%;	p<0.001),	high	grade	tumors	(50	vs.	31%;	
p<0.001),	lymphovascular	invasion	(LVI:	64	vs.	45%;	p=0.01),	and	positive	lymph	nodes	(LN:	60	vs.	43%;	
p=0.009).	Receipt	of	adjuvant	chemotherapy	was	similar	between	the	groups	(49	vs.	49%).	Non-IGBC	was	
associated	with	worse	median	OS	compared	to	IGBC	(17	vs.	32	months,	p<0.001),	which	persisted	among	
Stage	III	patients	(12	vs.	29	months;	p<0.001),	but	not	Stages	I,	II	or	IV.	After	adjustment	of	other	adverse	
pathologic	factors	(grade,	T-stage,	LVI,	margin,	LN),	adjuvant	chemotherapy	was	associated	with	
improved	OS	only	in	Stage	III	IGBC	but	not	in	non-IGBC.	
	
CONCLUSION		
	
Compared	to	incidental	discovery,	non-incidental	gallbladder	cancer	is	associated	with	reduced	overall	
survival,	which	is	most	evident	in	Stage	III	disease.	Despite	being	well-matched	for	other	adverse	
pathologic	factors,	adjuvant	chemotherapy	was	associated	with	improved	survival	only	in	Stage	III	
patients	with	incidentally	discovered	cancer.	This	underscores	the	importance	of	method	of	diagnosis	in	
gallbladder	cancer	and	suggests	that	these	two	groups	may	represent	a	distinct	biology	of	disease,	and	
the	same	treatment	paradigm	may	not	be	appropriate.	
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CHAPTER	I:	INTRODUCTION	
	 Gallbladder	cancer	(GBC)	is	a	rare	disease	and	is	the	sixth	most	common	gastrointestinal	
malignancy	in	the	U.S.1	Overall,	it	is	associated	with	a	poor	prognosis	and	an	estimated	5-year	survival	of	
5-13%.2,3	Surgery	is	the	only	potentially	curative	therapy	for	GBC,	yet	5-year	survival	following	resection	
varies	from	10%	to	as	high	as	100%,	depending	on	tumor	biology,	stage	of	disease,	and	extent	of	
resection.2,4-6	In	50-70%	of	GBC	patients,	the	diagnosis	is	made	incidentally	on	pathologic	examination	
after	routine	cholecystectomy	for	presumed	benign	disease.7,8	In	fact,	incidental	GBC	(IGBC)	is	found	in	
approximately	1	in	every	150	resected	cholecystectomy	specimens.9	Based	on	current	management	
guidelines,	re-resection	is	recommended	for	all	IGBC	patients	with	T1b,	T2,	and	T3	disease.10		
For	the	remaining	30-50%	of	GBC	patients,	the	diagnosis	is	made	non-incidentally	in	the	pre-
operative	setting,	typically	after	signs	and	symptoms	concerning	for	malignancy	develop,	such	as	jaundice	
and	weight	loss.	In	general,	non-IGBC	is	thought	to	portend	a	worse	prognosis	than	IGBC,	primarily	
because	non-IGBC	patients	tend	to	present	in	later	stages	of	disease	that	are	often	less	amenable	to	
curative	resection.8,11,12	Whether	these	observed	survival	differences	are	merely	due	to	more	advanced	
disease	in	non-IGBC	patients	or,	rather,	are	due	to	distinct	tumor	biology	is	unclear.	Few	studies	focus	in	
detail	on	the	clinicopathologic	and	survival	differences	between	non-IGBC	and	IGBC,	and	those	studies	
that	do	are	often	limited	to	single	institution	series	and	small	patient	cohorts.11,12	Furthermore,	while	
there	are	data	that	suggest	chemotherapy	may	improve	survival	in	advanced	GBC	and	in	the	adjuvant	
setting,	the	role	of	chemotherapy	in	the	context	of	resected	IGBC	versus	non-IGBC	is	not	known.13,14		
The	purpose	of	this	large,	multi-institutional	study	was	to	compare	clinicopathologic	factors,	
management	strategies,	and	survival	between	patients	undergoing	resection	for	IGBC	and	non-IGBC.	
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CHAPTER	II:	METHODS	
DATA	SOURCES	
	 The	U.S.	Extrahepatic	Biliary	Malignancy	Consortium	(USEBMC)	is	a	cooperative	group	of	ten	U.S.	
academic	institutions:	Emory	University,	Johns	Hopkins	University,	New	York	University,	Ohio	State	
University,	Stanford	University,	University	of	Louisville,	University	of	Wisconsin,	Vanderbilt	University,	
Wake	Forest	University,	and	Washington	University	in	St.	Louis.	All	patients	with	GBC	who	underwent	
resection	from	January	2000	to	March	2015	were	assessed.	Only	patients	who	had	information	regarding	
method	of	diagnosis	(incidental	or	non-incidental)	were	included	for	analysis.	Thirty-day	mortalities	were	
excluded.		
Pertinent	baseline	demographic,	perioperative,	and	pathologic	data	were	collected	from	a	
retrospective	review	of	patient	medical	records.	The	variables	are	described	in	detail	below.	Each	
institution	obtained	Institutional	Review	Board	(IRB)	approval	prior	to	data	collection.	
BASELINE	PATIENT	DEMOGRAPHICS	AND	MEDICAL	HISTORY	VARIABLES	
Gender	was	recorded	as	male	or	female.	Age	(years)	was	determined	after	calculating	the	
difference	between	the	date	of	surgery	and	date	of	birth.	Race	was	recorded	as	African-American,	White,	
Latino,	or	Other.	Body	mass	index	(kg/m2)	was	calculated	after	considering	height	(m)	and	weight	(kg)	at	
the	time	of	surgery.	Past	medical	history	for	specific	conditions	were	recorded	as	a	yes	or	no	in	the	
database.	However,	for	modeling	purposes,	a	new	variable	named	comorbidities	was	created.	Number	of	
comorbidities	were	recorded	as	0,	1,	or	³2	and	considered	history	of	hypertension	(HTN),	diabetes	(DM),	
prior	cardiac	event,	congestive	heart	failure	(CHF),	severe	chronic	obstructive	pulmonary	disorder	
(COPD),	and	end-stage	renal	disease	(ESRD).	History	of	HTN	was	recorded	as	yes	if	the	patient	required	
medication	within	30	days	prior	to	surgery.	History	of	diabetes	(DM)	was	recorded	as	yes	if	patients	
required	either	oral	medication	or	insulin.	No	history	of	DM	or	diet-controlled	diabetes	was	coded	as	no.	
Prior	cardiac	event	was	recorded	as	yes	if	a	patient	experienced	any	of	the	following:	angina	within	one	
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month	of	surgery,	myocardial	infarction	within	six	months	of	surgery,	coronary	intervention	at	any	time,	
or	any	major	cardiac	surgery	(excluding	pacemaker	and	AICD).	Congestive	heart	failure	(CHF)	was	
recorded	as	yes	if	the	patient	had	newly	diagnosed	CHF	or	acute	exacerbation	of	CHF	within	30	days	prior	
to	surgery.	Severe	chronic	obstructive	pulmonary	disorder	(COPD)	was	recorded	as	yes	if	the	COPD	
resulted	in	one	of	the	following:	functional	disability,	prior	hospitalization	for	COPD,	chronic	
bronchodilator	therapy,	or	forced	expiratory	volume	in	one	second	(FEV1)	was	less	than	75%.	Asthma,	
interstitial	fibrosis	and	sarcoidosis	were	recorded	as	no	for	COPD.	End	stage	renal	disease	was	recorded	
as	yes	if	patient	had	acute	or	chronic	renal	failure	requiring	peritoneal	dialysis,	hemodialysis,	
hemofiltration,	or	ultrafiltration	within	two	weeks	of	surgery.		
BASELINE	PERIOPERATIVE	VARIABLES	
	 Clinical	jaundice	was	recorded	as	yes	or	no	if	the	patient	had	presence	of	jaundice	at	any	point	in	
the	30-day	preoperative	period.	Diagnostic	laparoscopy	was	recorded	as	yes	if	it	was	performed	prior	to	
or	at	the	time	of	resection.	Additionally,	distant	disease	was	recorded	as	yes	if	distant	disease	was	seen	
on	either	diagnostic	laparoscopy	or	exploratory	laparoscopy.	Attempted	resection	was	recorded	as	yes	if	
resection	of	the	primary	tumor	was	attempted.	Completed	resection	was	recorded	as	yes	if	resection	of	
the	primary	tumor	was	successfully	completed.	Type	of	resection	was	recorded	as	bile	duct	only,	
cholecystectomy	only,	partial	hepatectomy	with	portal	lymphadenectomy,	or	major	hepatectomy.	
Estimated	blood	loss	(mL)	was	recorded	after	resection	was	completed.	Major	complications	were	
recorded	as	yes	if	the	Clavien-Dindo	Grade	was	greater	than	or	equal	to	IIIa	within	90	days	after	date	of	
surgery.	The	Clavien-Dindo	Grade	is	determined	by	the	following	scale:	Grade	I:	no	intervention,	Grade	II:	
medication	only,	Grade	IIIa:	procedure	not	requiring	general	anesthesia,	Grade	IIIb:	procedure	requiring	
general	anesthesia,	Grade	IVa:	intensive	care	unit,	single-organ	dysfunction,	Grade	IVb:	intensive	care	
unit,	multi-organ	dysfunction,	Grade	V:	death.	Length	of	stay	(days)	was	calculated	by	determining	the	
difference	from	the	date	of	discharge	and	date	of	surgery.		
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PATHOLOGIC	VARIABLES	
Pathologic	analysis	was	performed	by	experienced	gatrointestinal	(GI)	pathologists	at	each	
institution	at	the	time	of	surgery.	Final	margin	status	was	recorded	as	R0	(no	residual	disease),	R1	
(microscopic	residual	disease),	or	R2	(macroscopic	residual	disease).	The	tumor	(T)	stage	of	gallbladder	
cancer	was	based	on	the	American	Joint	Committee	(AJCC)	7th	edition	definition	for	primary	tumors	
(Figure	1A).15	Primary	tumor	definition	for	gallbladder	cancer	is	defined	as	follows:	Tis:	carcinoma	in	situ,	
T1a:	tumor	invades	into	lamina	propria,	T1b:	tumor	invades	into	muscular	layer,	T2:	tumor	invades	into	
perimuscular	connective	tissue	with	no	extension	beyond	serosa	or	into	liver,	T3:	tumor	perforates	
through	serosa/visceral	peritoneum	and/or	directly	invades	the	liver	and/or	one	other	adjacent	organ	or	
structure,	such	as	the	stomach,	duodenum,	colon,	pancreas,	omentum,	or	extrahepatic	ducts,	T4:	tumor	
invades	main	portal	vein	or	hepatic	artery	or	invades	two	or	more	extrahepatic	organs	or	structures.		
Grade	was	reported	as	well-differentiated,	moderately-differentiated,	poorly-differentiated,	and	
undifferentiated.	However,	for	analyses	purposes,	grade	was	coded	as	low,	intermediate,	or	high.	Low	
grade	included	patients	who	were	well-differentiated.	Intermediate	grade	included	patients	that	were	
moderately-differentiated	while	patients	with	high	grade	included	poorly-differentiated	and	
undifferentiated	patients.	Lymphovascular	invasion	(LVI)	and	perineural	invasion	(PNI)	were	recorded	as	
yes	if	it	was	present	according	to	the	pathology	report.	The	number	of	lymph	nodes	was	recorded	if	
lymph	nodes	were	sampled.	If	lymph	nodes	were	positive	for	disease,	it	was	recorded	as	yes.	More	
specifically,	if	N1	(regional)	lymph	nodes	were	positive,	then	it	was	indicated	as	yes	under	the	
corresponding	column.	N1	(regional)	lymph	nodes	include	those	in	the	hilar,	cystic	duct,	and	
pericholedochal	nodes.	If	N2	lymph	nodes	were	sampled,	then	it	was	indicated	as	a	yes.	N2	lymph	nodes	
include	those	that	are	periportal,	periduodenal,	peripancreatic,	celiac,	and	superior	mesenteric	nodes.	
Additionally,	if	N2	nodes	were	positive,	this	was	indicated	under	the	corresponding	column.	Staging	was	
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based	on	the	American	Joint	Committee	on	Cancer	(AJCC)	7th	edition	guidelines	by	using	the	determined	
primary	(T)	tumor,	regional	lymph	node	(N),	and	distant	metastasis	(M)	characteristics	(Figure	1A-D).15		
FIGURE	1A-D.	American	Joint	Committee	on	Cancer	(AJCC)	7th	Edition	Definitions	and	Anatomical	Staging	
for	Gallbladder	Cancer	
FIGURE	1A.	Primary	Tumor	(T)	Definition	for	Gallbladder	Cancer	
Primary	Tumor	(T)	Stage	 Description	
TX	 Primary	tumor	cannot	be	assessed	
T0	 No	evidence	of	primary	tumor	
Tis	 Carcinoma	in	situ	
T1	 Tumor	invades	lamina	propria	or	muscular	layer	
T1a	 Tumor	invades	lamina	propria			
T1b	 Tumor	invades	muscular	layer	
T2	
Tumor	invades	perimuscular	connective	tissue;	no	extension	
beyond	serosa	or	into	liver	
T3	
Tumor	perforates	the	serosa	(visceral	peritoneum)	and/or	
directly	invades	the	liver	and/or	one	other	adjacent	organ	or	
structure,	such	as	the	stomach,	duodenum,	colon,	pancreas,	
omentum,	or	extra	hepatic	bile	ducts	
T4	
Tumor	invades	main	portal	vein	or	hepatic	artery	or	invades	two	
or	more	extra	hepatic	organs	or	structures		
	
FIGURE	1B.	Regional	Lymph	Nodes	(N)	Definition	for	Gallbladder	Cancer	
Regional	Lymph	Nodes	(N)	Stage	 Description	
NX	 Regional	lymph	nodes	cannot	be	assessed	
N0	 No	regional	lymph	node	metastasis	
N1	
Metastases	to	nodes	along	the	cystic	duct,	common	bile	
duct,	hepatic	artery,	and/or	portal	vein	
N2	
Metastases	to	periaortic,	pericaval,	superior	mesenteric	
artery,	and/or	celiac	artery	lymph	nodes	
	
FIGURE	1C.	Distant	Metastasis	(M)	Definition	for	Gallbladder	Cancer	
Distant	Metastasis	(M)	Stage	 Description	
M0	 No	distant	metastasis	
M1	 Distant	metastasis	
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FIGURE	1D.	American	Joint	Committee	on	Cancer	(AJCC)	7th	Edition	Anatomic	Staging	for				
Gallbladder	Cancer	
AJCC	7th	Edition	Anatomic	Staging	for	Gallbladder	Cancer	
	 Primary	Tumor	(T)	 Regional	Lymph	Nodes	(N)	 Distant	Metastasis	(M)	
Stage	0	 Tis	 N0	 M0	
Stage	I	 T1	 N0	 M0	
Stage	II	 T2	 N0	 M0	
Stage	IIIA	 T3	 N0	 M0	
Stage	IIIB	 T1-3	 N1	 M0	
Stage	IVA	 T4	 N0-1	 M0	
Stage	IVB	
Any	T	
Any	T	
N2	
Any	N	
M0	
M1	
	
NEOADJUVANT	AND	ADJUVANT	THERAPY	VARIABLES	
Data	regarding	neoadjuvant	therapy,	adjuvant	therapy,	disease	recurrence,	and	survival	were	
additionally	recorded.	Neoadjuvant	chemotherapy	was	recorded	as	yes	if	chemotherapy	was	given	pre-
operatively.	Neoadjuvant	radiotherapy	was	recorded	as	yes	if	radiation	was	given	pre-operatively.	
Adjuvant	chemotherapy	was	recorded	as	yes	of	chemotherapy	was	given	post-operatively.	Adjuvant	
radiotherapy	was	recorded	as	yes	if	radiation	was	given	post-operatively.		
DISEASE	RECURRENCE	AND	SURVIVAL	VARIABLES	
	 Recurrence	was	recorded	as	yes	if	the	patient	had	any	recurrence.	More	specifically,	if	the	patient	
had	locoregional	recurrence,	it	was	recorded	as	yes	under	the	corresponding	column.	Local	recurrence	is	
defined	as	recurrence	in	the	same	place	the	primary	tumor	was	found	or	very	close	by.	The	cancer	has	
not	spread	to	the	lymph	nodes	or	other	parts	of	the	body.	Regional	recurrence	is	defined	as	recurrence	in	
the	lymph	nodes	and	tissue	located	in	the	vicinity	of	the	primary	tumor.	Distant	recurrence	was	also	
recorded	as	yes/no.	Distant	recurrence	is	defined	as	any	recurrence	that	has	spread	to	areas	farther	away	
from	the	primary	tumor.	This	includes	places	such	as	the	liver,	lung,	peritoneum,	and	brain.		
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Survival	information	was	verified	when	necessary	using	the	Social	Security	Death	Index.	Death	
was	recorded	as	yes	or	no.	Overall	survival	(months)	was	calculated	from	the	date	of	surgery	to	the	date	
of	death	from	any	cause.				
STATISTICAL	ANALYSIS	
The	primary	objective	was	to	assess	the	association	of	IGBC	and	non-IGBC	with	overall	survival	
(OS).	The	secondary	objectives	were	to	compare	clinicopathologic	factors	between	cohorts,	and	assess	
the	association	of	adjuvant	therapy	with	OS	stratified	by	method	of	diagnosis.	All	statistical	analysis	was	
conducted	using	SAS	9.4	(SAS	Institute	Inc.,	Cary,	NC).	Patients	with	IGBC	and	non-IGBC	were	compared	
using	chi-squared	analyses	for	categorical	variables	and	Student’s	t-tests	for	continuous	variables.	
Categorical	variables	included	the	following:	gender,	race,	comorbidities,	clinical	jaundice,	diagnostic	
laparoscopy,	distant	disease	on	exploration,	attempted	resection,	completed	resection,	type	of	resection,	
major	complications,	final	margin	status,	AJCC	T-Stage,	grade,	lymphovascular	invasion,	perineural	
invasion,	any	lymph	node	positive,	N1	(regional)	node	positive,	N2	(distant)	node	sampled,	N2	(distant)	
node	positive,	AJCC	anatomic	stage,	neoadjuvant	chemotherapy,	neoadjuvant	radiotherapy,	adjuvant	
chemotherapy,	adjuvant	radiotherapy,	locoregional	recurrence,	and	distant	recurrence.	Continuous	
variables	included:	age,	BMI,	estimated	blood	loss,	length	of	stay,	and	number	of	lymph	nodes	retrieved.	
The	mean	and	standard	deviation	were	recorded	for	continuous	variables.			
Univariable	and	multivariable	Cox-proportional	hazard	regression	analyses	were	performed	to	
assess	the	association	of	individual	pathologic	factors	and	method	of	diagnosis	with	OS.	Baseline	patient	
demographics	were	analyzed	to	determine	the	study	population’s	representativeness	to	the	main	
population.	Baseline	past	medical	history	variables	were	considered,	because	these	variables	may	have	
affected	the	OS	results.	Patients	with	increased	comorbidities	tend	to	have	more	complications	that	may	
affect	their	OS.	Univariable	variables	were	chosen	based	on	their	clinicopathologic	relevance.	Univariable	
Cox-proportional	hazard	regression	included	non-incidental	versus	incidental,	clinical	jaundice,	margin	
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positive	(R1),	grade,	AJCC	T-Stage,	lymph	node	positive,	lymphovascular	invasion,	perineural	invasion,	and	
adjuvant	chemotherapy.	Variables	that	were	statistically	significant	(two-tailed	p<0.05)	were	included	in	
multivariable	Cox-proportional	hazard	regression	analyses.	Log-rank	analyses	were	performed	to	
compare	OS	distribution	between	IGBC	and	non-IGBC	cohorts,	which	were	displayed	using	Kaplan-Meier	
survival	plots.		
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CHAPTER	III:	RESULTS	
	 Of	449	patients	with	GBC,	445	(99%)	had	data	regarding	method	of	diagnosis	and	were	included	
for	analysis.	Then	mean	age	of	the	entire	cohort	was	65	years	and	65%	were	female.	GBC	was	diagnosed	
incidentally	in	266	(60%)	patients,	and	non-incidentally	in	179	(40%).			
ALL	PATIENTS	
	 Comparative	analyses	of	baseline	demographics	and	clinicopathologic	factors	between	IGBC	and	
non-IGBC	are	shown	in	Table	1.	Compared	to	IGBC,	patients	with	non-IGBC	had	lower	body	mass	indexes	
at	the	time	of	resection	(26	kg/m2	vs	30	kg/m2;	p<0.001),	and	were	more	likely	to	be	of	non-white	race	
(36%	vs	21%;	p<0.001)	and	present	with	clinical	jaundice	(40%	vs	10%;	p<0.001).	Non-IGBC	was	also	more	
frequently	associated	with	finding	distant	disease	at	surgical	exploration	(36%	vs	17%;	p<0.001),	aborted	
procedures	(43%	vs	18%;	p<0.001),	and	major	hepatectomies	(19%	vs	5%;	p<0.001).	Aborted	procedures	
included	resections	that	could	not	be	completed.		
	 On	pathology,	non-IGBC	was	associated	with	a	higher	incidence	of	R1	(17%	vs	6%)	and	R2	(43%	vs	
19%;	p<0.001)	resections,	advanced	AJCC	T-stage	(T3/T4:	70%	vs	40%;	p<0.001),	poor	tumor	
differentiation	(50%	vs	31%;	p=0.001),	and	lymphovascular	invasion	(64%	vs	45%;	p=0.01).	Despite	similar	
lymph	node	yields	between	groups,	non-IGBC	patients	more	frequently	had	lymph	node	positive	disease	
compared	to	IGBC	patients	(60%	vs	43%;	p=0.009).	AJCC	Stage	IV	disease	was	also	more	common	in	non-
IGBC	than	in	IGBC	(57%	vs	28%;	p<0.001).		
	 There	was	no	difference	between	non-IGBC	and	IGBC	in	the	receipt	of	neoadjuvant	therapy	(5%	
vs	3%;	p=0.54)	or	adjuvant	therapy	(54%	vs	52%;	p=0.85).	Of	those	patients	who	received	adjuvant	
chemotherapy	(total	n=164),	67%	were	treated	with	a	gemcitabine-based	regimen,	and	no	difference	was	
seen	between	groups.	Disease	recurrence	was	more	common	in	non-IGBC	than	IGBC	(50%	vs	35%;	
p=0.04),	but	there	was	no	difference	in	the	region	of	recurrence,	with	distant	disease	recurrence	being	
the	most	common	in	both	groups	(86%	vs	82%;	p=0.43).	
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TABLE	1:	Comparison	of	Clinciopathologic	Variables	between	Patients	with	Incidental	Gallbladder	
Cancer	versus	Non-Incidental	Gallbladder	Cancer	
Baseline	Variables	
Incidental	
(n=266,	60%)	
Non-Incidental	
(n=179,	40%)	
p-value	
Age	(yrs),	mean	±	SD	 65	±	12	 66	±	11	 0.63	
Male,	n	(%)	 99	(37)	 57	(32)	 0.29	
BMI	(kg/m2),	mean	±	SD	 30	±	7		 26	±	6	 <0.001	
Race,	n	(%)	
					White	
					African-American	
					Latino	
					Other	
	
194	(79)	
27	(11)	
15	(6)	
9	(4)	
	
108	(64)	
26	(16)	
9	(5)	
25	(15)	
<0.001	
	
	
	
	
Comorbiditiesᐩ,	n	(%)		
					0		
					1	
					≥	2	
	
69	(30)	
96	(42)	
63	(28)	
	
58	(39)	
		59	(40) 	
32	(22)	
0.17	
	
	
	
Clinical	Jaundice,	n	(%)	 24	(10)	 65	(40)	 <0.001	
Diagnostic	Laparoscopy,	n	(%)	 80	(30)	 71	(40)	 0.05	
Distant	Disease	on	Exploration,	n	(%)	 45	(17)	 63	(36)	 <0.001	
Attempted	Resection,	n	(%)	 235	(88)	 142	(79)	 0.01	
Completed	Resection,	n	(%)	 217	(82)	 102	(57)	 <0.001	
Type	of	Resection,	n	(%)	
					Bile	Duct	Only	
					Cholecystectomy	Only	
					Partial	Hepatectomy	+	Portal	LN	
					Major	Hepatectomy	
	
9	(4)	
23	(10)	
182	(81)	
11	(5)	
	
1	(1)	
40	(30)	
69	(51)	
25	(19)	
<0.001	
	
	
	
	
EBL	(mL),	mean	±	SD	 337	±	346	 389	±	617	 0.37	
Major	Complication‡,	n	(%)	 37	(16)	 33	(21)	 0.25	
Length	of	Stay	(days),	mean	±	SD	 7.1	±	8.1	 9.1	±	8.9	 0.01	
Final	Margin	Status,	n	(%)	
					R0	
					R1	
					R2	
	
198	(75)	
16	(6)	
50	(19)	
	
71	(40)	
31	(17)	
77	(43)	
<0.001	
	
	
	
AJCC	T-Stage	
					Tis/T1a	
					T1b	
					T2	
					T3	
					T4	
	
9	(4)	
14	(6)	
116	(50)	
80	(35)	
11	(5)	
	
5	(4)	
4	(3)	
31	(23)	
65	(48)	
30	(22)	
<0.001	
	
	
	
	
	
Grade,	n	(%)	
					Low		
					Intermediate	
					High	
	
24	(12)	
116	(57)	
62	(31)	
	
9	(7)	
60	(43)	
70	(50)	
	
0.001	
	
	
	
Lymphovascular	Invasion,	n	(%)	 53	(45)	 65	(64)	 0.01	
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Perineural	Invasion,	n	(%)	 63	(53)	 62	(62)	 0.20	
#	Lymph	Nodes	Retrieved,	mean	±	SD	 4.8	±	5.5	 4.7	±	8.0	 0.82	
Any	Lymph	Node	Positive,	n	(%)	 86	(43)	 65	(60)	 0.009	
N1	(Regional)	Node	Positive,	n	(%)	 82	(41)	 60	(56)	 0.02	
N2	(Distant)	Node	Sampled,	n	(%)	 54	(23)	 20	(12)	 0.01	
N2	(Distant)	Node	Positive,	n	(%)	 14	(19)	 8	(29)	 0.41	
AJCC	Anatomic	Stage,	n	(%)	
					Stage	0	
					Stage	I	
					Stage	II	
					Stage	IIIA	
					Stage	IIIB	
					Stage	IVA	
					Stage	IVB	
	
7	(3)	
12	(6)	
51	(23)	
28	(13)	
59	(27)	
9	(4)	
53	(24)	
	
1	(1)	
6	(4)	
11	(7)	
16	(11)	
30	(20)	
18	(12)	
68	(45)	
<0.001	
	
	
	
	
	
	
	
Neoadjuvant	Therapy,	n	(%)	
					Chemotherapy	
					Radiation	
8	(3)	
8	(3)	
1	(0)	
8	(5)	
8	(5)	
3	(2)	
0.54	
0.58	
0.34	
Adjuvant	Therapy,	n	(%)	
					Chemotherapy	
					Radiation	
103	(52)	
99	(49)	
48	(25)	
69	(54)	
65	(49)	
23	(19)	
0.85	
1.00	
0.26	
Recurrence,	n	(%)	
					Locoregional	Only	
					Distant	
60	(35)	
11	(18)	
49	(82)	
38	(50)	
5	(14)	
30	(86)	
0.04	
0.43	
	
ᐩ	Includes	hypertension,	prior	cardiac	event,	congestive	heart	failure,	diabetes,	chronic	obstructive	
pulmonary	disease,	and	end-stage	renal	disease	
‡	≥	Clavien-Dindo	Grade	IIIa	
BMI,	body	mass	index;	AJCC,	American	Joint	Committee	on	Cancer	
	
SURVIVAL	ANALYSIS	
	 Median	follow-up	for	survivors	was	12.3	months	(IQR,	2.5–37.5).	Median	OS	among	all	patients	
was	18.7	months	(95%		CI,	16.3–21.1).	Median	OS	among	only	patients	who	underwent	curative-intent	
resections	(R0	and	R1	resections)	were	24.3	months	(95%	CI,	19.4–29.2).	Non-IGBC	was	associated	with	
worse	median	OS	(17.2	months;	95%	CI,	13.0–21.3)	compared	to	IGBC	(32.4	months;	95%	CI,	23.3–41.4;	
p=0.001;	Figure	2).	The	results	of	univariable	and	multivariable	Cox	proportional	hazard	modeling	for	OS	
are	shown	in	Table	2.	Non-IGBC	persisted	as	a	poor	prognostic	factor	(HR	2.27;	95%	CI,	1.15–4.46;	
p=0.02)	in	multivariable	analysis,	as	did	T3	and	T4	disease,	and	lymphovascular	invasion,	but	not	margins	
status,	tumor	grade,	lymph	node	status,	or	perineural	invasion.		
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FIGURE	2:	Kaplan-Meier	Survival	Curve	for	Overall	Survival	in	Patients	with	Incidental	(IGBC)	versus	Non-
Incidental	Gallbladder	Cancer	(non-IGBC).	Patients	with	non-IGBC	had	worst	median	overall	survival	(17	
months)	compared	to	patients	with	IGBC	(32	months).	Log-rank	p=0.001.	Excludes	30-day	mortalities	and	
R2	resections.	
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TABLE	2.	Univariable	and	Multivariable	Cox	Regression	Analysis	for	Overall	Survival	Among	All	
Curative	Intent	Resectionsᐩ	
	 						Univariable	Cox	Regression	 						Multivariable	Cox	Regression	
Variable	 HR	(95%	CI)	 p-value	 HR	(95%	CI)	 p-value	
Non-Incidental	vs.	
Incidental	
1.74	(1.26	-	2.40)	 0.001	 2.27	(1.15	-	4.46)	 0.02	
Clinical	Jaundice	 2.39	(1.57-3.64)	 <0.001	 0.79	(0.36	-	1.72)	 0.55	
Margin	Positive	 3.58	(2.45	-	5.22)	 <0.001	 0.85	(0.39	-	1.84)	 0.68	
Grade	
					Low	
					Intermediate	
					High	
	
Reference	
1.97	(0.98	-	3.94)	
2.98	(1.47	-	6.04)	
	
	
0.06	
0.002	
	
Reference	
0.76	(0.22	-	2.60)	
0.87	(0.25	-	3.00)	
	
	
0.66	
0.82	
AJCC	T-Stage	
					T1	
					T2	
					T3	
					T4	
	
Reference	
1.90	(0.85	-	4.20)	
5.39	(2.48	-	11.74)	
8.22	(3.35	-	20.21)	
	
	
0.12	
<0.001	
<0.001	
	
Reference	
3.83	(0.73	–	20.27)	
11.95	(2.24	–	63.85)	
11.37	(1.78	–	72.74)	
	
	
0.11	
0.004	
0.01	
Lymph	Node	Positive	 1.93	(1.37	-	2.72)	 <0.001	 1.28	(0.68	-	2.39)	 0.44	
Lymphovascular	
Invasion	
2.33	(1.53	-	3.54)	 <0.001	 1.87	(0.96	-	3.66)	 0.07	
Perineural	Invasion	 2.34	(1.51	-	3.63)	 <0.001	 1.42	(0.71	-	2.84)	 0.32	
Adjuvant	
Chemotherapy	
0.92	(0.63	-	1.35)	 0.68	 -	 -	
ᐩExcludes	aborted/R2	resections	
HR,	hazard	ratio;	CI,	confidence	interval;	AJCC,	American	Joint	Committee	on	Cancer	
	
STAGE-SPECIFIC	ANALYSIS	
	 On	stratum-specific	analysis	by	AJCC	stage,	non-IGBC	was	associated	with	worse	median	OS	only	
among	patients	with	Stage	III	disease	(11.6	months	vs	28.6	months;	p<0.001),	but	not	Stages	I,	II,	or	IV	
(Figure	3A-D).	Comparing	clinicopathologic	variables	between	non-IGBC	to	IGBC	among	Stage	III	only,	
non-IGBC	patients	were	more	likely	to	have	R1	resections	(36%	vs	9%;	p=0.001),	but	there	was	no	
difference	in	the	distribution	of	tumor	grade,	T-stage,	lymph	node	status,	lymphovascular	invasion,	
perineural	invasion,	or	receipt	of	adjuvant	chemotherapy	between	groups.	On	univariable	Cox-
proportional	hazard	regression	analysis,	non-IGBC,	positive	margin,	and	T3	disease	were	associated	with	
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worse	OS,	while	adjuvant	therapy	was	associated	with	improved	survival.	Only	non-IGBC	(HR	2.53;	95%	CI,	
1.21–4.23;	p=0.01)	and	adjuvant	therapy	persisted	on	multivariable	analysis	(Table	3).		
Figure	3A-D.	Kaplan-Meier	Survival	Curve	for	Overall	Survival	in	Patients	with	Incidental	versus	Non-
Incidental	Gallbladder	Cancers,	Stratified	by	Stage.	A)	Stage	I,	log-rank	p=0.89.	B)	Stage	II,	log-rank	p=0.16.	
C)	Stage	III,	log-rank	p<0.001.	D)	Stage	IV,	log-rank	p=0.72.	Excludes	30-day	mortalities	and	R2	resections.	
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TABLE	3.	Univariable	and	Multivariable	Cox	Regression	Analysis	for	Overall	Survival	Among	Only	Stage	III	
Curative-Intent	Resectionsᐩ	
Variable	 Univariable	Cox	Regression	 Multivariable	Cox	Regression	
	 HR	(95%)	 p-value	 HR	(95%	CI)	 p-value	
Non-Incidental	vs.	Incidental	 3.01	(1.87	-	4.84)	 <0.001	 2.53	(1.21	-	4.23)	 0.01	
Clinical	Jaundice	 1.50	(0.84	–	2.69)	 0.17	 -	 -	
Margin	Positive	 2.77	(1.62	-	4.71)	 <0.001	 1.78	(0.84	-	3.76)	 0.13	
Grade	
					Low	
					Intermediate	
					High	
	
Reference	
0.84	(0.30	-	2.38)	
0.98	(0.34	-	2.81)	
	
	
0.74	
0.97	
	
	
-	
-	
	
	
-	
-	
AJCC	T-Stage	
					T1‡	
					T2	
					T3	
	
-	
Reference	
1.97	(1.13	-	3.45)	
	
-	
-	
0.02	
	
-	
Reference	
1.52	(0.75	-	3.08)	
	
-	
-	
0.25	
Lymph	Node	Positive	 1.01	(0.62	-	1.63)	 0.98	 -	 -	
Lymphovascular	Invasion	 1.37	(0.71	-	2.65)	 0.35	 -	 -	
Perineural	Invasion	 1.49	(0.75	-	2.98)	 0.25	 -	 -	
Adjuvant	Chemotherapy	 0.45	(0.26	-	0.77)	 0.004	 0.48	(0.27	-	0.84)	 0.01	
ᐩ	Excludes	AJCC	Stages	I,	II,	and	IV,	and	aborted/R2	resections	
‡	Insufficient	number	of	patients	for	analysis	
HR,	hazard	ratio;	CI,	confidence	interval;	AJCC,	American	Joint	Committee	on	Cancer	
	
ADJUVANT	CHEMOTHERAPY	
	 Adjuvant	chemotherapy	was	associated	with	improved	median	OS	only	among	patients	with	
Stage	III	disease	(30.4	months	vs	14.1	months;	p=0.003),	but	not	Stages	I,	II,	or	IV,	or	among	the	whole	
cohort	of	patients	who	underwent	curative-intent	resections.	When	stratified	by	method	of	diagnosis	
among	only	Stage	III	patients,	adjuvant	chemotherapy	was	associated	with	improved	median	OS	for	IGBC	
(30.5	months	vs	15.9	months;	p=0.03;	Figure	4A),	but	not	for	non-IGBC	(15.1	months	vs	10.4	months;	
p=0.23;	Figure	4B).	
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FIGURE	4A-B.	Kaplan-Meier	Survival	Curve	for	Overall	Survival	in	Stage	III	Patients	Who	Received	Adjuvant	
Chemotherapy	versus	No	Adjuvant	Chemotherapy,	Stratified	by	Method	of	Diagnosis.	A)	Incidental	
gallbladder	cancer,	log-rank	p=0.03.	B)	Non-incidental	gallbladder	cancer,	log-rank	p=0.23.	Excludes	30-
day	mortalities	and	R2	resections.	
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CHAPTER	IV:	DISCUSSION	
	 Gallbladder	cancer	is	a	rare	disease	with	an	overall	poor	prognosis.	Because	of	its	rarity,	studies	
examining	important	clinicopathologic	factors	and	management	strategies	for	GBC	are	often	limited	to	
single-institution	series	and	small	patient	cohorts.	In	this	study,	we	utilized	a	large,	multi-institutional	
database	to	investigate	the	importance	of	method	of	diagnosis	(incidental	versus	non-incidental)	in	
relation	to	other	prognostic	factors	on	overall	survival.	We	found	that,	overall,	non-IGBC	was	associated	
with	more	advanced	disease	than	IGBC,	yet	even	accounting	for	other	poor	prognostic	factors,	it	was	still	
independently	associated	with	worse	OS.	On	stage-specific	analysis,	non-IGBC	was	associated	with	worse	
OS	only	among	Stage	III	patients,	but	not	Stages	I,	II,	and	IV.	Although	not	associated	with	survival	among	
all	patients,	adjuvant	therapy	was	also	associated	with	improved	OS	among	only	Stage	III	patients.	On	
further	analysis,	we	found	that	adjuvant	therapy	was	associated	with	improved	OS	only	among	Stage	III	
IGBC	patients,	but	not	Stage	III	non-IGBC	patients.		
	 In	general,	non-IGBC	carries	a	worse	prognosis	than	IGBC,	as	patients	tend	to	be	diagnosed	in	
later	stages	of	disease	after	more	ominous	symptomatology	has	developed.8,11,12	In	a	study	by	Shih	et	al.,	
patients	with	non-IGBC	were	more	likely	to	present	with	jaundice,	weight	loss,	and	Stages	III	and	IV	
disease,	and	less	likely	to	undergo	R0	resections	than	those	with	IGBC.11	As	expected,	non-IGBC	was	
associated	with	worse	median	OS	(8	months)	compared	to	IGBC	(21	months).	This	survival	difference	
persisted	on	sub-set	analyses	of	only	patients	who	underwent	curative-intent	resections	and	those	with	
Stage	II	disease,	as	well	as	on	a	multivariable	analysis	of	patients	who	underwent	at	least	a	partial	
hepatectomy.	However,	this	study	included	a	total	of	only	107	patients,	only	67	of	whom	underwent	
resection,	and	no	consideration	was	given	to	the	role	of	chemotherapy.	Furthermore,	few	other	modern	
studies	explore	in	detail	the	clinicopathologic	and	potential	biologic	factors	that	may	influence	the	
observed	survival	difference	between	IGBC	and	non-IGBC,	and	most	are	similarly	limited	by	low	numbers	
of	patients.	Pawlik	et	al.	demonstrated	a	significant	survival	difference	between	non-IGBC	and	IGBC,	but	
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focused	primarily	on	patients	in	the	latter	cohort,	and	not	on	the	differences	between	the	two.8	In	a	
single-institution	series	by	Cziupka	et	al.,	the	median	OS	for	non-IGBC	was	6.7	months	compared	to	22.3	
months	for	IGBC.	Yet	this	study	only	included	a	total	of	42	patients,	and	method	of	diagnosis	was	not	
examined	beyond	the	context	of	metastatic	disease	and	R2	resections.12		
	 In	the	current	study	of	445	patients,	266	had	IGBC	and	179	had	non-IGBC.	Similar	to	Shih	et	al.,	
we	found	that	non-IGBC	was	associated	with	indicators	of	more	advanced	disease	and	known	poor	
prognostic	factors:	clinical	jaundice,	distant	disease	on	exploration,	aborted	procedures,	major	
hepatectomy,	positive	margins,	advanced	T-stage	and	disease	stage,	high	tumor	grade,	lymphovascular	
invasion,	and	positive	lymph	nodes.	After	excluding	aborted	procedures	and	non-curative-intent	
resections,	non-IGBC	was	still	associated	with	worse	OS	than	IGBC,	which	persisted	on	multivariable	
analysis	accounting	for	all	other	significant	pathologic	factors.	Unlike	Shih	et	al.,	however,	our	study	
demonstrated	a	survival	difference	only	among	Stage	III	patients,	and	not	Stages	I,	II,	or	IV.	In	fact,	among	
the	Stage	III	cohort,	only	method	of	diagnosis	(non-IGBC	versus	IGBC)	and	adjuvant	therapy	were	
associated	with	survival	on	both	univariable	and	multivariable	analyses,	while	margin	status,	tumor	grade,	
T-stage,	lymph	node	status,	lymphovascular	invasion,	or	perineural	invasion	were	not.	These	differences	
in	survival	may	represent	distinct	tumor	biology	between	IGBC	and	non-IGBC.	As	demonstrated	by	others,	
IGBC	is	associated	with	gallstone	disease	and	chronic	inflammation	whereas	non-IGBC	is	not.	Differences	
between	inflammation-mediated	tumorigenesis	have	translated	to	differences	in	survival	in	gastric	
cancer.	In	a	six-institution	study	by	Postlewait	et	al.,	patients	with	gastric	cancer	who	also	had	a	history	of	
Helicobacter	pylori	(H.	pylori),	which	causes	chronic	inflammation	and	gastritis,	demonstrated	better	
overall	survival	than	those	with	gastric	cancer	who	did	not	have	a	history	of	H.	pylori	infection	(84.3	
months	vs	44.2	months;	p	=	0.008).21	In	2009,	Marrelli	et	al.	followed	an	Italian	cohort	of	297	patients	
after	resection	of	gastric	adenocarcinoma.22	They	found	that	patients	with	H.	pylori	infection	had	
significantly	longer	OS.	They	further	stratified	the	patients	into	the	different	stages	and	continued	to	
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obtain	the	same	results.	Additionally,	Meimarkais	et	al.	followed	166	German	patients	during	10	years	
and	found	that	patients	with	H.	pylori	infection	had	both	longer	OS	and	recurrence-free	survival	(RFS),	
independent	of	other	known	prognostic	factors.23		
Determining	the	mechanisms	is	beyond	the	scope	of	this	study,	but	the	differences	in	the	tumors	
that	develop	from	H.	pylori	acting	as	carcinogen	and	variability	of	the	immune	response	could	contribute	
to	the	outcome	disparities	in	gastric	cancer.	There	are	multiple	molecular	subtypes	of	gastric	
adenocarcinoma,	one	of	which	is	microsatellite	instability.24,	25	Studies	have	illustrated	that	microsatellite	
instability	is	associated	with	improved	OS	in	gastric	adenocarcinoma	patients.26	Hayden	et	al.	studied	the	
prevalence	of	microsatellite	instability	in	two	geographically	distinct	European	populations	and	found	that	
it	was	more	common	in	the	population	with	the	higher	rate	of	H.	pylori	infection	and	postulated	that	H.	
pylori	could	play	a	role	in	the	development	of	microsatellite	instability.27	Furthermore,	tumor	immunology	
may	be	an	explanation	for	the	survival	disparities.	Both	Xue	et	al.	and	Rad	et	al.	postulated	that	H.	pylori	
infection	leads	to	a	better	prognosis	in	gastric	adenocarcinoma	secondary	to	increased	immunity	against	
tumor	cells	and	decreased	action	or	regulatory	T	cells.28.29	Chen	et	al.	found	that	patients	with	higher	
levels	of	Th1	cells	in	resected	gastric	adenocarcinoma	had	increased	OS	and	RFS.30	Although	the	exact	
roles	of	H.	pylori	infection	and	the	associated	inflammation	in	gastric	cancer	development	and	outcomes	
are	unclear,	the	authors	and	others	have	postulated	that	they	may	lead	to	distinct	molecular	subtype	of	
gastric	cancer	and	increase	the	immune	system	response	to	malignancy.	Thus,	there	may	be	a	potential	
parallel	with	gallbladder	cancer,	where	patients	who	have	gallstones	and	chronic	inflammation	(IGBC)	
demonstrate	better	survival	than	those	who	do	not	(non-IGBC).		
	 Adjuvant	therapy	after	resection	has	increasingly	become	a	topic	of	interest	for	GBC	patients,	yet	
results	from	various	studies	have	been	mixed.16-20	A	recent	meta-analysis	of	ten	retrospective	studies	
evaluating	adjuvant	therapy	compared	to	surgery	alone	for	resected	GBC	demonstrated	that,	although	
there	was	no	improvement	in	survival	for	the	entire	cohort,	adjuvant	therapy	was	associated	with	
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improved	survival	among	patients	with	R1	resections,	lymph	node	positive	disease,	and	combined	Stages	
II	and	III.14	However,	the	studies	included	a	mixture	of	single-	and	multimodality	therapies,	and	subset	
analyses	for	margin	and	nodal	status	were	based	on	results	from	only	1-2	studies.	Furthermore,	all	of	the	
studies	that	showed	a	positive	association	between	adjuvant	therapy	and	survival	were	from	Asian	
countries,	which	may	limit	the	applicability	of	their	results	to	Western	populations,	and	none	of	them	
evaluated	adjuvant	therapy	in	the	context	of	method	of	diagnosis.		
	 In	the	current	study,	adjuvant	chemotherapy,	with	or	without	radiation,	was	administered	to	
approximately	half	of	patients,	and	two-thirds	of	those	were	treated	with	Gemcitabine-based	regimens.	
Adjuvant	chemotherapy	was	only	associated	with	improved	OS	among	Stage	III	patients,	but	not	among	
all	patients	who	underwent	curative-intent	resections,	or	those	with	Stages	I,	II,	or	IV	disease.	When	
further	stratified,	adjuvant	therapy	was	specifically	only	associated	with	improved	OS	in	Stage	III	IGBC,	
and	not	Stage	III	non-IGBC,	despite	the	cohorts	being	relatively	well-matched.	As	previously	mentioned,	
among	the	Stage	III	cohort,	both	method	of	diagnosis	and	adjuvant	chemotherapy	were	the	only	factors	
associated	with	survival	on	multivariable	analysis,	even	after	accounting	for	other	known	adverse	
pathologic	factors,	such	as	margin	status	and	T-Stage.	This	may	only	be	seen	in	Stage	III	patients,	because	
Stage	I	and	II	patients	may	do	too	well	to	detect	a	difference	while	Stage	IV	patients	do	too	poorly	to	
detect	the	difference.		
	 This	study	has	several	limitations.	Its	retrospective	nature	makes	disease	recurrence	and	survival	
data	challenging	to	capture,	and	introduces	a	selection	bias	that	makes	it	difficult	to	draw	definitive	
conclusions	from	our	results.	However,	this	is	one	of	the	largest	studies	that	compares	IGBC	and	non-
IGBC,	and	includes	data	from	ten	geographically-diverse,	academic	institutions,	which	eliminates	single-
institution	bias,	and	more	closely	represents	the	general	practice	patterns	and	disease	characteristics	of	
the	United	States.	Furthermore,	to	our	knowledge,	this	is	largest	and	only	study	that	examines	the	role	of	
adjuvant	therapy	in	the	context	of	method	of	diagnosis.	Although	pathologic	analysis	was	not	
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standardized	across	institutions,	all	involved	academic	centers	have	experienced	gastrointestinal	
pathologist	who	performed	the	pathologic	review.		
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CHAPTER	V:	CONCLUSIONS	
	 In	conclusion,	compared	to	incidental	discovery,	non-incidental	gallbladder	cancer	is	associated	
with	reduced	overall	survival,	which	is	evident	specifically	in	Stage	III	disease.	Despite	being	well-matched	
and	accounting	for	other	adverse	pathologic	factors,	adjuvant	chemotherapy	was	associated	with	
improved	survival	only	in	Stage	III	patients	with	incidental	gallbladder	cancer,	and	not	in	those	with	non-
incidental	gallbladder	cancer.	This	underscores	the	importance	of	method	of	diagnosis	in	gallbladder	
cancer	and	suggests	that	these	two	groups	may	represent	distinct	tumor	biologies	that	require	unique	
treatment	paradigms.	Further	tissue-based	studies	should	be	performed	to	investigate	the	potential	
differences	in	pathophysiology	and	tumorigenesis	between	incidental	and	non-incidental	gallbladder	
cancer,	and	current	ongoing	and	future	adjuvant	therapy	trials	should	consider	the	potential	influence	of	
method	of	diagnosis	in	their	analyses	and	trial	design.		
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APPENDIX	A:	FIGURES	
	
FIGURE	1A-D.	American	Joint	Committee	on	Cancer	(AJCC)	7th	Edition	Definitions	and	Anatomical	Staging	
for	Gallbladder	Cancer	
FIGURE	1A.	Primary	Tumor	(T)	Definition	for	Gallbladder	Cancer	
Primary	Tumor	(T)	Stage	 Description	
TX	 Primary	tumor	cannot	be	assessed	
T0	 No	evidence	of	primary	tumor	
Tis	 Carcinoma	in	situ	
T1	 Tumor	invades	lamina	propria	or	muscular	layer	
T1a	 Tumor	invades	lamina	propria			
T1b	 Tumor	invades	muscular	layer	
T2	
Tumor	invades	perimuscular	connective	tissue;	no	extension	
beyond	serosa	or	into	liver	
T3	
Tumor	perforates	the	serosa	(visceral	peritoneum)	and/or	
directly	invades	the	liver	and/or	one	other	adjacent	organ	or	
structure,	such	as	the	stomach,	duodenum,	colon,	pancreas,	
omentum,	or	extra	hepatic	bile	ducts	
T4	
Tumor	invades	main	portal	vein	or	hepatic	artery	or	invades	
two	or	more	extra	hepatic	organs	or	structures		
	
FIGURE	1B.	Regional	Lymph	Nodes	(N)	Definition	for	Gallbladder	Cancer	
Regional	Lymph	Nodes	(N)	Stage	 Description	
NX	 Regional	lymph	nodes	cannot	be	assessed	
N0	 No	regional	lymph	node	metastasis	
N1	
Metastases	to	nodes	along	the	cystic	duct,	
common	bile	duct,	hepatic	artery,	and/or	portal	
vein	
N2	
Metastases	to	periaortic,	pericaval,	superior	
mesenteric	artery,	and/or	celiac	artery	lymph	
nodes	
	
FIGURE	1C.	Distant	Metastasis	(M)	Definition	for	Gallbladder	Cancer	
Distant	Metastasis	(M)	Stage	 Description	
M0	 No	distant	metastasis	
M1	 Distant	metastasis	
	
	
	
  28	
FIGURE	1D.	American	Joint	Committee	on	Cancer	(AJCC)	7th	Edition	Anatomic	Staging	for				
Gallbladder	Cancer	
Anatomic	Stage/Prognostic	Groups	
	 Primary	Tumor	(T)	 Regional	Lymph	Nodes	(N)	 Distant	Metastasis	(M)	
Stage	0	 Tis	 N0	 M0	
Stage	I	 T1	 N0	 M0	
Stage	II	 T2	 N0	 M0	
Stage	IIIA	 T3	 N0	 M0	
Stage	IIIB	 T1-3	 N1	 M0	
Stage	IVA	 T4	 N0-1	 M0	
Stage	IVB	
Any	T	
Any	T	
N2	
Any	N	
M0	
M1	
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FIGURE	2:	Kaplan-Meier	Survival	Curve	for	Overall	Survival	in	Patients	with	Incidental	versus									
Non-Incidental	Gallbladder	Cancer.	Patients	with	non-incidental	gallbladder	cancer	had	worst	
median	overall	survival	(17	months)	compared	to	patients	with	incidental	gallbladder	cancer	(32	
months).	Log-rank	p=0.001.	Excludes	30-day	mortalities	and	R2	resections.	
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FIGURE	3A-D.	Kaplan-Meier	Survival	Curve	for	Overall	Survival	in	Patients	with	Incidental	versus	Non-
Incidental	Gallbladder	Cancers,	Stratified	by	Stage.	A)	Stage	I,	log-rank	p=0.89.		
B)	Stage	II,	log-rank	p=0.16.	C)	Stage	III,	log-rank	p<0.001.	D)	Stage	IV,	log-rank	p=0.05.	Excludes	30-day	
mortalities	and	R2	resections.	MNR,	median	not	reported.	
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FIGURE	4A-B.	Kaplan-Meier	Survival	Curve	for	Overall	Survival	in	Stage	III	Patients	Who	Received	Adjuvant	
Chemotherapy	versus	No	Adjuvant	Chemotherapy,	Stratified	by	Method	of	Diagnosis.	A)	Incidental	
gallbladder	cancer,	log-rank	p=0.03.	B)	Non-incidental	gallbladder	cancer,	log-rank	p=0.23.	Excludes	30-
day	mortalities	and	R2	resections.	
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APPENDIX	B:	TABLES	
TABLE	1:	Comparison	of	Clinciopathologic	Variables	between	Patients	with	Incidental	Gallbladder	
Cancer	versus	Non-Incidental	Gallbladder	Cancer	
Baseline	Variables	
Incidental	
(n=266,	60%)	
Non-Incidental	
(n=179,	40%)	
p-value	
Age	(yrs),	mean	±	SD	 65	±	12	 66	±	11	 0.63	
Male,	n	(%)	 99	(37)	 57	(32)	 0.29	
BMI	(kg/m2),	mean	±	SD	 30	±	7	 26	±	6	 <0.001	
Race,	n	(%)	
					White	
					African-American	
					Latino	
					Other	
	
194	(79)	
27	(11)	
15	(6)	
9	(4)	
	
108	(64)	
26	(16)	
9	(5)	
25	(15)	
<0.001	
	
	
	
	
Comorbiditiesᐩ,	n	(%)		
					0		
					1	
					≥	2	
	
69	(30)	
96	(42)	
63	(28)	
	
58	(39)	
59	(40) 	
32	(22)	
0.17	
	
	
	
Clinical	Jaundice,	n	(%)	 24	(10)	 65	(40)	 <0.001	
Diagnostic	Laparoscopy,	n	(%)	 80	(30)	 71	(40)	 0.05	
Distant	Disease	on	Exploration,	n	(%)	 45	(17)	 63	(36)	 <0.001	
Attempted	Resection,	n	(%)	 235	(88)	 142	(79)	 0.01	
Completed	Resection,	n	(%)	 217	(82)	 102	(57)	 <0.001	
Type	of	Resection,	n	(%)	
					Bile	Duct	Only	
					Cholecystectomy	Only	
					Partial	Hepatectomy	+	Portal	LN	
					Major	Hepatectomy	
	
9	(4)	
23	(10)	
182	(81)	
11	(5)	
	
1	(1)	
40	(30)	
69	(51)	
25	(19)	
<0.001	
	
	
	
	
EBL	(mL),	mean	±	SD	 337	±	346	 389	±	617	 0.37	
Major	Complication‡,	n	(%)	 37	(16)	 33	(21)	 0.25	
Length	of	Stay	(days),	mean	±	SD	 7.1	±	8.1	 9.1	±	8.9	 0.01	
Final	Margin	Status,	n	(%)	
					R0	
					R1	
					R2	
	
198	(75)	
16	(6)	
50	(19)	
	
71	(40)	
31	(17)	
77	(43)	
<0.001	
	
	
	
AJCC	T-Stage	
					Tis/T1a	
					T1b	
					T2	
					T3	
					T4	
	
9	(4)	
14	(6)	
116	(50)	
80	(35)	
11	(5)	
	
5	(4)	
4	(3)	
31	(23)	
65	(48)	
30	(22)	
<0.001	
	
	
	
	
	
Grade,	n	(%)	
					Low		
					Intermediate	
					High	
	
24	(12)	
116	(57)	
62	(31)	
	
9	(7)	
60	(43)	
70	(50)	
0.001	
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Lymphovascular	Invasion,	n	(%)	 53	(45)	 65	(64)	 0.01	
Perineural	Invasion,	n	(%)	 63	(53)	 62	(62)	 0.20	
#	Lymph	Nodes	Retrieved,	mean	±	SD	 4.8	±	5.5	 4.7	±	8.0	 0.82	
Any	Lymph	Node	Positive,	n	(%)	 86	(43)	 65	(60)	 0.009	
N1	(Regional)	Node	Positive,	n	(%)	 82	(41)	 60	(56)	 0.02	
N2	(Distant)	Node	Sampled,	n	(%)	 54	(23)	 20	(12)	 0.01	
N2	(Distant)	Node	Positive,	n	(%)	 14	(19)	 8	(29)	 0.41	
AJCC	Anatomic	Stage,	n	(%)	
					Stage	0	
					Stage	I	
					Stage	II	
					Stage	IIIA	
					Stage	IIIB	
					Stage	IVA	
					Stage	IVB	
	
7	(3)	
12	(6)	
51	(23)	
28	(13)	
59	(27)	
9	(4)	
53	(24)	
	
1	(1)	
6	(4)	
11	(7)	
16	(11)	
30	(20)	
18	(12)	
68	(45)	
<0.001	
	
	
	
	
	
	
	
Neoadjuvant	Therapy,	n	(%)	
					Chemotherapy	
					Radiation	
8	(3)	
8	(3)	
1	(0)	
8	(5)	
8	(5)	
3	(2)	
0.54	
0.58	
0.34	
Adjuvant	Therapy,	n	(%)	
					Chemotherapy	
					Radiation	
103	(52)	
99	(49)	
48	(25)	
69	(54)	
65	(49)	
23	(19)	
0.85	
1.00	
0.26	
Recurrence,	n	(%)	
					Locoregional	Only	
					Distant	
60	(35)	
11	(18)	
49	(82)	
38	(50)	
5	(14)	
30	(86)	
0.04	
0.43	
	
ᐩ	Includes	hypertension,	prior	cardiac	event,	congestive	heart	failure,	diabetes,	chronic	obstructive	
pulmonary	disease,	and	end-stage	renal	disease	
‡	≥	Clavien-Dindo	Grade	IIIa	
BMI,	body	mass	index;	AJCC,	American	Joint	Committee	on	Cancer	
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TABLE	2.	Univariable	and	Mutivariable	Cox	Regression	Analysis	for	Overall	Survival	Among	All	
Curative	Intent	Resectionsᐩ	
Variable	 Univariable	Cox	Regression	 Multivariable	Cox	Regression	
	 HR	(95%	CI)	 p-value	 HR	(95%	CI)	 p-value	
Non-Incidental	vs.	
Incidental	
1.74	(1.26	-	2.40)	 0.001	 2.27	(1.15	-	4.46)	 0.02	
Clinical	Jaundice	 2.39	(1.57-3.64)	 <0.001	 0.79	(0.36	-	1.72)	 0.55	
Margin	Positive	 3.58	(2.45	-	5.22)	 <0.001	 0.85	(0.39	-	1.84)	 0.68	
Grade	
					Low	
					Intermediate	
					High	
	
Reference	
1.97	(0.98	-	3.94)	
2.98	(1.47	-	6.04)	
	
	
0.06	
0.002	
	
Reference	
0.76	(0.22	-	2.60)	
0.87	(0.25	-	3.00)	
	
	
0.66	
0.82	
AJCC	T-Stage	
					T1	
					T2	
					T3	
					T4	
	
Reference	
1.90	(0.85	-	4.20)	
5.39	(2.48	-	11.74)	
8.22	(3.35	-	20.21)	
	
	
0.12	
<0.001	
<0.001	
	
Reference	
3.83	(0.73	–	20.27)	
11.95	(2.24	–	63.85)	
11.37	(1.78	–	72.74)	
	
	
0.11	
0.004	
0.01	
Lymph	Node	Positive	 1.93	(1.37	-	2.72)	 <0.001	 1.28	(0.68	-	2.39)	 0.44	
Lymphovascular	
Invasion	
2.33	(1.53	-	3.54)	 <0.001	 1.87	(0.96	-	3.66)	 0.07	
Perineural	Invasion	 2.34	(1.51	-	3.63)	 <0.001	 1.42	(0.71	-	2.84)	 0.32	
Adjuvant	
Chemotherapy	
0.92	(0.63	-	1.35)	 0.68	 -	 -	
ᐩExcludes	aborted/R2	resections	
HR,	hazard	ratio;	CI,	confidence	interval;	AJCC,	American	Joint	Committee	on	Cancer	
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TABLE	3.	Univariable	and	Multivariable	Cox	Regression	Analysis	for	Overall	Survival	Among	Only	Stage	III	
Curative-Intent	Resectionsᐩ	
Variable	 Univariable	Cox	Regression	 Multivariable	Cox	Regression	
	 HR	(95%)	 p-value	 HR	(95%	CI)	 p-value	
Non-Incidental	vs.	Incidental	 3.01	(1.87	-	4.84)	 <0.001	 2.53	(1.21	-	4.23)	 0.01	
Clinical	Jaundice	 1.50	(0.84	–	2.69)	 0.17	 -	 -	
Margin	Positive	 2.77	(1.62	-	4.71)	 <0.001	 1.78	(0.84	-	3.76)	 0.13	
Grade	
					Low	
					Intermediate	
					High	
	
Reference	
0.84	(0.30	-	2.38)	
0.98	(0.34	-	2.81)	
	
	
0.74	
0.97	
	
	
-	
-	
	
	
-	
-	
AJCC	T-Stage	
					T1‡	
					T2	
					T3	
	
-	
Reference	
1.97	(1.13	-	3.45)	
	
-	
-	
0.02	
	
-	
Reference	
1.52	(0.75	-	3.08)	
	
-	
-	
0.25	
Lymph	Node	Positive	 1.01	(0.62	-	1.63)	 0.98	 -	 -	
Lymphovascular	Invasion	 1.37	(0.71	-	2.65)	 0.35	 -	 -	
Perineural	Invasion	 1.49	(0.75	-	2.98)	 0.25	 -	 -	
Adjuvant	Chemotherapy	 0.45	(0.26	-	0.77)	 0.004	 0.48	(0.27	-	0.84)	 0.01	
ᐩ	Excludes	AJCC	Stages	I,	II,	and	IV,	and	aborted/R2	resections	
‡	Insufficient	number	of	patients	for	analysis	
HR,	hazard	ratio;	CI,	confidence	interval;	AJCC,	American	Joint	Committee	on	Cancer	
	
	
	
	
	
